Ramses condoms' comparative strength claims "unsubstantiated" -- FTC consent agreement.
This article was originally published in The Gray Sheet
Executive SummaryRAMSES CONDOM COMPARATIVE CLAIMS BARRED BY PROPOSED FTC AGREEMENT unless Norcross, Georgia-based London International "possesses and relies upon competent and reliable scientific evidence to back up the claims" for the latex condoms, the Federal Trade Commission reported Sept. 3. The consent agreement was spurred by advertising claims that Ramses is "30% stronger than the leading brand," which FTC called "unsubstantiated and deceptive."
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.